COVID-19
Excerpt from the Press Release: SAN DIEGO, Aug. 26, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19, today announced promising preclinical results for its mRNA vaccine against SARS-CoV-2. STI-mRNA is comprised of proprietary designer Spike-encoding mRNAs to…
Read More
Excerpt from the Press Release: SAN JOSE, Calif., Aug. 25, 2021 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that a genomic variant analysis indicates that its potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2. While…
Read More
Excerpt from the Press Release: In February, the National Institutes of Health terminated an ambitious clinical trial to study the effectiveness of COVID-19 convalescent plasma in treating patients with mild to moderate disease. The therapy, the NIH determined, showed little benefit in an interim analysis. In a new paper published on Aug. 18 in The New England Journal…
Read More
Excerpt from the Press Release: If you thought you were familiar with the SARS-CoV-2 spike protein, think again. According to a new study, the spike protein has a secret feature—a starting gate. It consists of glycans. When the gate is closed, the spike protein’s receptor binding domain (RBD) stays hidden, safe from the prying eyes…
Read More
Excerpt from the Press Release: Immunization with a protein-based immunogen, DYAI-100, a receptor binding domain (RBD) of SARS-CoV-2, resulted in potent B cell immunity in preclinical studies, with strong serological recognition of the original SARS-CoV-2 virus and major variants of concern (Alpha, Beta, Gamma, and Delta; “VOCs”). The sera of vaccinated mice demonstrated potent neutralization…
Read More
Excerpt from the Press Release: Since the early days of the COVID pandemic, scientists have aggressively pursued the secrets of the mechanisms that allow severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter and infect healthy human cells. Early in the pandemic, University of California San Diego’s Rommie Amaro, a computational biophysical chemist, helped develop…
Read More
Excerpt from the Press Release: Gritstone bio is developing Covid-19 vaccines that use self-amplifying messenger RNA, which is intended to further boost the immune response compared to mRNA alone. The company also says its vaccine candidates may be able to protect against variants of the novel coronavirus. As coronavirus variants continue to fuel the ongoing…
Read More
Excerpt from the Press Release: The FDA wanted a couple more clinical studies for Qualigen’s investigational COVID-19 antiviral before human testing, but the biotech is calling it quits instead. Shares of the company plunged nearly 20% to $1.34 as the markets opened Tuesday, underscoring the risk that small companies take on when trying to jump…
Read More
Excerpt from the Press Release: SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, announced today the availability of a presentation on its corporate website to provide an overview of Sorrento’s proprietary mRNA vaccine development program for COVID-19.…
Read More
Excerpt from the Press Release: Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic’s lead COVID-19 vaccine candidate. Dyadic’s lead COVID-19 Vaccine, DYAI-100,…
Read More